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Background. Elevated plasma total homocysteine, an indepen-
dent risk factor for cardiovascular disease, is commonly observed
in renal patients. We have previously shown that the kidney is a
major site for the removal of plasma homocysteine in the rat. The
present investigation was performed to further characterize the
capacity of the kidney to handle acute elevations in plasma
homocysteine concentrations.
Methods. Acute hyperhomocysteinemic conditions (4- to
7-fold . controls) in rats were produced by either a primed-
continuous infusion of L-homocysteine or exposure to 80:20%
nitrous oxide:oxygen, which results in the inhibition of methionine
synthase.
Results. At physiological homocysteine concentrations, approx-
imately 15% of the arterial plasma homocysteine was removed on
passage through the kidney. Renal homocysteine uptake was
approximately 85% of the filtered load. The urinary excretion of
homocysteine was negligible (,2%). During acute hyperhomo-
cysteinemia produced by the infusion of L-homocysteine, renal
homocysteine uptake was increased fourfold and was equivalent
to 50% of the infused dose, while urinary excretion remained
negligible. Renal homocysteine uptake during nitrous oxide-
induced hyperhomocysteinemia increased threefold, with urinary
excretion remaining negligible.
Conclusions. These results provide strong evidence that the
kidney has a significant capacity for metabolizing acute elevations
in plasma homocysteine, and support a very limited role for the
re-methylation pathway in renal homocysteine metabolism.
Several recent epidemiological studies have provided
strong evidence that an increased total plasma homocys-
teine concentration is linked to an increased incidence of
cardiovascular disease [1, 2]. Homocysteine, a sulfur-
containing amino acid, is derived from the intracellular
metabolism of the indispensable amino acid methionine.
Once formed, homocysteine can be re-methylated back
to methionine via the cobalamin-dependent enzyme me-
thionine synthase (EC 2.1.1.13), which requires methyl-
tetrahydrofolate as a co-factor, or via the enzyme be-
taine:homocysteine methyltransferase (EC 2.1.1.5) [3].
Alternatively, homocysteine can enter the transulfura-
tion pathway and be converted to the amino acid cys-
teine, through the combined actions of two vitamin
B6-dependent enzymes: cystathionine-b-synthase (EC
4.2.1.22) and cystathionine-g-lyase (EC 4.4.1.1) [4]. An
increase in the plasma concentration of homocysteine
likely reflects perturbations in the cellular metabolism of
this amino acid, leading to an increased rate of cellular
export, a decreased rate of cellular uptake and metabo-
lism, or a combination of these factors.
Several factors are known to lead to increased plasma
concentrations of homocysteine, including deficiencies of
folate, cobalamin, and vitamin B6, mutations of enzymes in
the metabolic pathway, pharmacological agents [5], and
certain disease states. Increased plasma homocysteine con-
centrations have been documented in human patients with
end-stage renal disease [6–8]. These patients are known to
be in a higher risk category for atherothrombotic events [9],
and the observed hyperhomocysteinemia is likely to play a
key role. Poor nutritional status of individuals with renal
disease may predispose them to the development of hyper-
homocysteinemia [10]. Additionally, the loss of kidney
function may signify a role for this tissue in the metabolic
clearance of plasma homocysteine. We, in collaboration
with other researchers, examined the uptake of homocys-
teine across the rat kidney and documented significantly
higher concentrations of homocysteine in arterial plasma
compared to those in the renal vein [11]. The minimal rates
of homocysteine excretion observed provided strong evi-
dence that homocysteine was metabolized by renal tubule
cells, an observation supported by in vitro studies [12, 13].
While the arteriovenous difference for homocysteine was
small (' 1 mM), it represented 20% of the arterial plasma
concentration, positioning the kidney as an important
tissue in the metabolic disposal of plasma homocysteine.
However, it is not known what reserve capacity the kidney
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possesses to deal with elevated plasma homocysteine con-
centrations. To address this question, we investigated ho-
mocysteine flux across the rat kidney during acute hyper-
homocysteinemia, induced by either a primed-continuous
infusion of L-homocysteine, or by the exposure of rats to
the anesthetic gas nitrous oxide, which inactivates the
cobalamin-dependent methionine synthase [14].
METHODS
Animals
Male Sprague-Dawley rats, weighing between 400 and
500 grams, were used throughout this study. The animals
were obtained from our institute’s breeding colony, and
were housed and treated in accordance with the Canadian
Council of Animal Care’s guidelines [15], as enforced by
our institute’s Animal Care Committee. Rats were fed a
20% casein-based diet, formulated to the specifications of
the AIN-93 semipurified diet [16], designed to meet the
nutritional requirements for growth of laboratory rats. The
diet and water were available ad libitum. Rats were housed
at 22°C and exposed to a 12 hour light:12 hour dark cycle,
with the dark cycle commencing at 20:00 hours. All exper-
iments were conducted immediately following the termina-
tion of the dark phase.
Chemicals
All chemicals (except where noted in the text) were
purchased from Sigma Chemical Co. (Oakville, ON, CAN).
Nitrous oxide exposure
For nitrous oxide exposure studies, rats were placed in a
cylindrical plexi-glass chamber (15 cm I.D. 3 60 cm)
through which was passed an 80% nitrous oxide:20%
oxygen gas mixture (total flow 5 5 liter/min). In previous
studies, a mixture of 50% nitrous oxide:50% oxygen gas
resulted in a significant reduction in liver methionine
synthase activity in rats after 30 minutes [14]. Furthermore,
in a recent study [17], rats tolerated exposure to an
atmosphere of 80% nitrous oxide:20% oxygen gas for an 18
hour period, indicating that our short term exposure times
should be well tolerated. For preliminary time course
studies, rats (N 5 3 per group) were kept in the chamber
for either 0 (air breathing controls), 60, 120, or 180
minutes. At the termination of the exposure period, rats
were allowed 60 minutes to recover in normal room air.
Following the recovery period, rats were anaesthetized with
an injection of sodium pentobarbital (60 mg/kg body wt i.p.;
Somnitol; MTC Pharmaceuticals, Cambridge, ON, Cana-
da), a mid-line abdominal incision was made and a blood
sample taken from the abdominal aorta into a heparinized
syringe and immediately placed on ice. Both kidneys were
rapidly excised, rinsed with an isotonic saline solution, and
frozen in liquid nitrogen until assayed for cystathionine-b-
synthase and methionine synthase. Blood samples were
centrifuged and the plasma collected and stored at 270°C
until analyzed for total homocysteine concentration.
Renal clearance studies
Animals were anesthetized with pentobarbital and surgi-
cally prepared for studies of renal clearance, as previously
described [18]. Briefly, following cannulation of the tra-
chea, catheters were placed into the left jugular vein (PE-50
tubing; Clay Adams, Parsippany, NJ, USA) and left ureter
(PE-10 tubing). A priming dose of 1.75 mCi of [carboxy-
14C]inulin (New England Nuclear, Lachine, Quebec, Can-
ada) in 0.8 ml of 5% mannitol-0.45% NaCl was injected
into the left saphenous vein. This was followed by a
continuous infusion of the same solution, through the
jugular catheter, at a rate of 0.037 ml/min, using a Harvard
Apparatus model 975 compact infusion pump. Following a
30-minute stabilization period, urine was collected from the
ureter catheter into a weighed micro-test tube, for a period
of 20 minutes. At the end of the 20-minute collection
period, 1 ml blood samples were withdrawn into heparin-
ized syringes from the left renal vein, followed by the
abdominal aorta, and the animals were killed by exsangui-
nation. Blood samples were immediately centrifuged at
12,000 g for five minutes to remove red blood cells. The
plasma was removed and either prepared immediately for
the measurement of free homocysteine concentrations or
stored at 270°C. Tubes containing the urine were weighed
and urinary output was determined as the difference in
weights before and after the collection period. Urine
samples were then stored at 270°C.
For studies involving L-homocysteine infusion, L-homo-
cysteine was included in the infusion solutions at concen-
trations calculated to provide 5 mmol/100 g body wt in the
prime, and 25 nmol/(min z 100 g body wt) in the continuous
infusion. In preliminary experiments, these infusion rates
were shown to result in sustained, increased plasma con-
centration of homocysteine by 30 minutes post-initiation of
the infusion (Fig. 1). When homocysteine was included in
the infusion solution, an equivalent amount of NaCl (os-
motic basis) was removed. L-homocysteine was prepared
from L-homocysteine thiolactone, as previously described
[19]. For studies involving nitrous oxide exposure, rats were
exposed to an atmosphere of 80% nitrous oxide:20%
oxygen gas, as described above, for 180 minutes, then
subjected to renal clearance studies. Timing of the studies
allowed for blood collection at 60 minutes following the
termination of nitrous oxide exposure.
Analyses
Plasma total (protein-bound, free-oxidized and free-
reduced) and free (oxidized and reduced) and urine total
homocysteine concentrations were determined by reverse-
phase HPLC and fluorescence detection of ammonium
7-fluorobenzo-2-oxa-1,3,diazole-4-sulphonate thiol ad-
ducts, using the method of Vester and Rasmussen [20]. For
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determination of 14C-inulin, 25 ml aliquots of plasma and
10 ml aliquots of urine were mixed with 10 ml of a liquid
scintillation cocktail (ScintiVerse; Fisher Scientific, Ne-
pean, ON, Canada), and total radioactivity was determined
by liquid scintillation counting (Model 1214 Rackbeta LSC;
LKB Wallac, Turku, Finland).
For the determination of kidney cystathionine b-syn-
thase and methionine synthase activities, 10% (wt/vol)
homogenates were made in 0.05 M potassium phosphate
buffer (pH 6.9). The tissue was homogenized with a
Polytron (Brinkman Instruments, Toronto, Canada) for
20 s at 50% output and centrifuged at 18,000 3 g at 4°C for
30 minutes. Supernatants were collected and assayed for
enzyme activities and total protein. Cystathionine-b-syn-
thase activities were measured by the method of Miller et al
[21], with cystathionine concentrations measured by re-
verse-phase HPLC, utilizing pre-column derivatization with
o-phthaldehyde and fluorescence detection [22]. Methio-
nine synthase activities were measured by the method of
Koblin et al [23]. Protein was measured using the biuret
method [24], after solubilization with deoxycholate [25].
Bovine serum albumin was used as a standard.
Calculations
Glomerular filtration rate and renal plasma flow were
calculated using the expressions derived by Wolf [26].
Renal uptake of homocysteine was computed as the prod-
uct of the arteriovenous (A-V) difference for total plasma
homocysteine and the renal plasma flow. The filtered load
of homocysteine was calculated as the product of the
glomerular filtration rate and the arterial plasma concen-
tration of free homocysteine, since it was assumed that
homocysteine bound to protein was unavailable for filtra-
tion. Homocysteine excretion was calculated as the product
of urinary total homocysteine concentration and the urine
flow. All values for calculated rates were expressed per 100
grams of rat body wt.
Statistics
Data were analyzed by ANOVA [27]. If the F-test value
for the model was significant (P , 0.05), treatment means
were compared by Student-Newman-Keul’s multiple com-
parisons procedure [28]. All results are presented as the
mean (SEM).
RESULTS
Development of acute hyperhomocysteinemia
The primed-continuous infusion of L-homocysteine re-
sulted in a prompt, dramatic rise in its plasma concentra-
tion. Thirty minutes following the initiation of the infusion,
plasma homocysteine concentrations were approximately
sevenfold higher than baseline values [58.06 (3.12) mM
versus 7.80 (0.98) mM), and were similar to values obtained
after 15 minutes of infusion [62.52 (5.14) mM].
The effect of exposure to 80% nitrous oxide:20% oxygen
gas on plasma homocysteine, and the activities of kidney
cystathionine-b-synthase and methionine synthase are de-
picted in Figure 1. Following 60 minutes of exposure (1 60
min recovery), the concentration of plasma homocysteine
was significantly elevated (.3-fold). Furthermore, the spe-
cific activity of kidney methionine synthase was reduced to
Fig. 1. Effect of exposure time to a 80:20%
nitrous oxide:oxygen gas atmosphere on total
plasma homocysteine concentrations (mM) and
kidney cystathionine b-synthase and
methionine synthase activities [nmol/(mg
protein z hr) in rats. Data are means plus SEM
(N 5 3 per time point). Different letter
superscripts within a bar series denote
statistically significant differences (P , 0.05) as
assessed by ANOVA and Student-Newman-
Keul’s multiple comparisons procedure.
Symbols are: (f) plasma total homocysteine;
(s) kidney cystathione b-synthase; (M) kidney
methionine synthase.
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15% of control values. After 120 minutes of exposure (1 60
min recovery), plasma homocysteine was further elevated
(.4-fold vs. controls), while methionine synthase activity
was 8% of control values. Plasma homocysteine concentra-
tions and kidney methionine synthase activity in rats ex-
posed for 180 minutes were not significantly different from
those values obtained after a 120-minute exposure period.
The specific activity of kidney cystathionine-b-synthase in
rats exposed to nitrous oxide for any of the time periods
was not significantly different from controls.
Renal hemodynamics
Renal hemodynamic parameters are presented in Table
1. There were no significant effects of either L-homocys-
teine infusion or nitrous oxide exposure on urine flow,
glomerular filtration rate, or renal plasma flow. The high
U:P ratio, calculated as the ratio of urinary 14C-inulin to
arterial plasma 14C-inulin, is indicative of active kidney
function, with greater than 99.6% of the glomerular filtrate
water being reabsorbed. The values for both glomerular
filtration rate and renal plasma flow are consistent with
those published previously by our lab [18, 29] and by others
[30].
Renal homocysteine metabolism
The arterial plasma homocysteine concentration was
significantly elevated by the infusion of L-homocysteine
(Table 2). There was a consistent, positive arteriovenous
difference for homocysteine, equivalent to approximately
15% of the total arterial plasma homocysteine concentra-
tion, in rats not infused with homocysteine (Table 2). In no
case was there a zero or negative arteriovenous difference
for homocysteine. The infusion of homocysteine resulted in
significantly higher arteriovenous difference values for ho-
mocysteine, which translated to renal uptake values of
homocysteine being significantly elevated by fourfold (Ta-
ble 2). The arterial plasma free homocysteine concentra-
tions were significantly elevated due to the infusion of
homocysteine (Table 2). The mean 6 SEM value for the
percentage of homocysteine found free in plasma was 75 6
3%, and was not affected by the infusion of homocysteine
(75 6 5%). The calculated filtered load of homocysteine
was also significantly elevated due to homocysteine infusion
(Table 2).
The acute hyperhomocysteinemia produced by exposing
rats to 80% nitrous oxide:20% oxygen gas for 180 minutes
yielded significantly higher renal homocysteine uptake val-
ues versus controls (Table 2). Similar to the situation in the
L-homocysteine-infused rats, arterial plasma free homocys-
teine concentrations, and the resulting filtered loads were
significantly higher in rats exposed to nitrous oxide com-
pared to controls. The mean 6 SEM value for the percent-
age of homocysteine found free in plasma was 65 6 2%.
Regression analysis yielded a significant relationship
(P , 0.05; r2 5 0.62) between arterial plasma total homo-
cysteine concentration and the renal homocysteine uptake
of homocysteine (Fig. 2). These data serve to further
highlight the ability of the rat kidney to handle acute
elevations in plasma homocysteine.
Homocysteine excretion
Both methods employed to generate an acute hyperho-
mocysteinemia resulted in significantly higher urinary ho-
mocysteine excretion rates versus those observed in control
rats (Table 2). Despite the higher excretion rates measured
in rats with hyperhomocysteinemia, homocysteine excre-
tion accounted for only 1, 2, and 1% of the filtered load of
homocysteine for control, L-homocysteine infused, and
nitrous oxide-exposed rats, respectively.
Table 1. Renal hemodynamic parameters of rats with acute
hyperhomocysteinemia resulting from either a primed-continuous
infusion of L-homocysteine (1HCY) or 3 hours of exposure to an
atmosphere of 80:20% nitrous oxide:oxygen gas (1N2O)
Parameter Units
Control
(N 5 8)
1HCY
(N 5 8)
1N2O
(N 5 7)
Body weight grams 455 448 421
(11) (4) (14)
Urine flow ml/(min z 100 g) 3.9 3.3 5.1
(0.4) (0.3) (0.9)
U:P ratio 232 252 213
(33) (19) (33)
Glomerular filtration
rate
ml/(min z 100 g) 0.85 0.87 1.02
(0.11) (0.12) (0.05)
Renal plasma flow ml/(min z 100 g) 3.32 3.77 4.13
(0.49) (0.50) (0.40)
Rates expressed as unit of volume per minute per 100 g body weight.
Values are expressed as means with standard errors presented in paren-
theses. Results from ANOVA F-test, P . 0.05.
Table 2. Renal homocysteine metabolism in rats with acute
hyperhomocysteinemia resulting from either a primed-continuous
infusion of L-homocysteine (1HCY) or 3 hours of exposure to an
atmosphere of 80:20% nitrous oxide:oxygen gas (1N2O)
Parameter Units
Control
(N 5 8)
1HCY
(N 5 8)
1N2O
(N 5 7)
Arterial HCY mM 7.94c 47.69a 33.42b
(0.64) (5.32) (1.13)
A-V Difference mM 1.14b 5.32a 2.80b
(0.32) (1.22) (0.45)
Renal HCY nmol/(min z 100 g) 4.12b 18.04a 12.04a
Uptake (1.65) (3.13) (2.65)
Arterial Plasma mM 5.95c 36.49a 21.89b
Free HCY (0.49) (4.77) (1.00)
Filtered Load of nmol/(min z 100 g) 5.41b 30.79a 22.21a
HCY (1.08) (4.95) (1.45)
HCY Excretion nmol/(min z 100 g) 0.068c 0.488a 0.170b
(0.010) (0.054 (0.010)
Rates expressed as nmoles of homocysteine per minute per 100 g body
weight. Values are expressed as means with standard errors presented in
parentheses. Values within rows with different superscripts are signifi-
cantly different (P , 0.05) by Student-Newman-Keul’s multiple compar-
isons procedure. Renal HCY uptake was calculated as the product of the
A-V difference and the renal plasma flow. The filtered load of HCY was
calculated as the product of the glomerular filtration rate and the free
HCY concentration.
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DISCUSSION
The concentration of homocysteine in plasma must
necessarily reflect a balance between its rate of appearance
in, and disappearance from, the plasma compartment. The
results of the present study strengthen our previous obser-
vation [11] that, in the rat, the kidney is a major site for the
removal of plasma homocysteine. At physiological homo-
cysteine concentrations, approximately 15% of the arterial
plasma homocysteine was removed on passage through the
kidney. The low rates of urinary homocysteine excretion
(,2% of filtered load) strongly indicate that the bulk of the
homocysteine taken up by the kidney is metabolized.
Furthermore, the renal uptake of homocysteine accounted
for approximately 85% of the filtered load, in rats receiving
no additional homocysteine. In these animals, renal homo-
cysteine uptake may be limited by the rates of glomerular
filtration. In humans, plasma total homocysteine concen-
trations have been shown to be highly negatively correlated
to glomerular filtration rates [31]. The close association
between renal uptake and the filtered load of homocysteine
observed in the present study may partially explain this
clinical finding, however this requires direct experimental
confirmation in humans.
During acute hyperhomocysteinemia, induced in the
present study by a primed-continuous infusion of L-homo-
cysteine, the renal uptake of homocysteine was increased
approximately fourfold over the rates observed at physio-
logical homocysteine concentrations. These results show
that the kidney has a substantial reserve capacity to deal
with increased plasma homocysteine concentrations. The
renal uptake of homocysteine, in the hyperhomocysteine-
mic rats, when corrected for the physiological rate of
homocysteine uptake, was approximately 14 nmol/(min z
100 g body wt), that is, renal uptake (1 HCY) 2 renal
uptake (control) (Table 2). This rate of homocysteine
uptake is greater than 50% of the homocysteine infused: 25
nmol/(min z 100 g body wt). These data highlight the
importance of renal homocysteine metabolism in relation
to the clearance of plasma homocysteine. Despite the
substantial uptake of homocysteine by the kidney, renal
uptake accounted for 60% of the filtered load during acute
hyperhomocysteinemia.
The in vivo fate of the homocysteine removed by the
kidney remains to be elucidated. We have recently shown
that, in incubations of isolated cortical tubules from rat
kidneys, greater than 80% of the measured L-homocysteine
disappearance was recovered in products of the transulfu-
ration pathway (cystathionine and cysteine) [12]. Methio-
nine appearance accounted for less than 2% of the homo-
cysteine disappearance. Similar results have been reported
by Foreman et al [13]. These data, from in vitro studies,
provide strong evidence that the transulfuration pathway
rather than the re-methylation pathway plays the major
role in metabolizing the homocysteine removed by the
kidney.
In order to explore the importance of the re-methylation
pathway to in vivo renal homocysteine metabolism, we
inactivated the cobalamin-dependent methionine synthase
by exposing rats to the anesthetic gas nitrous oxide. Methi-
onine synthase is the sole enzyme responsible for the
re-methylation of homocysteine to methionine in rat kid-
ney, due to the lack of betaine:homocysteine methyltrans-
ferase activity [32]. The mode of inactivation of methionine
synthase by nitrous oxide primarily involves the oxidation
of the cobalt atom of the cobalamin group to an inactive
state [33], thereby inhibiting the transfer of a methyl group,
originating in 5-methyltetrahydrofolate, to the homocys-
teine molecule. Nitrous oxide may also displace the cobal-
amin molecule from methionine synthase [34]. We ob-
served a huge reduction in the activity of kidney methionine
synthase between 0 and 120 minutes of nitrous oxide
exposure. Concurrently, there was a significant increase in
the plasma concentration of total homocysteine. Exposure
for an additional 60 minutes did not yield further significant
changes in either parameter. We also measured the activity
of liver methionine synthase and found that, following 60
minutes of exposure to nitrous oxide, the activity was 10%
of control values and did not decrease further upon pro-
longed exposure (data not shown). The observed decrease
in methionine synthase activity is consistent with results
published by others for in vivo studies [12, 15, 35]. Data on
the in vivo effects of nitrous oxide on plasma homocysteine,
especially for short-term exposure studies, are limited [36].
Our results are consistent with the notion that inhibiting
methionine synthase activity leads to a rapid increase in the
plasma concentration of homocysteine. However, to eval-
uate whether or not the inhibition of the re-methylation
pathway in rat kidney leads to a diminished capacity for
homocysteine metabolism in this organ, we measured the
uptake of homocysteine across the kidney of rats previously
Fig. 2. Regression analysis of arterial plasma total homocysteine concen-
tration versus renal homocysteine uptake. Data represent results from
rats from three treatment groups: control, 1HCY, 1N2O. Regression
equation: y 5 0.37x 1 0.55; P , 0.05, r2 5 0.62; N 5 23.
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exposed for 180 minutes to nitrous oxide. There was a
significant increase in the renal uptake of homocysteine
versus control rats, and this uptake represented 54% of the
filtered load, a value consistent with that observed in rats
infused with L-homocysteine. These data provide strong
evidence that the re-methylation pathway, via the cobal-
amin-dependent methionine synthase, is not a major factor
in the ability of the kidney to metabolize acute elevations in
plasma homocysteine. Furthermore, they serve to support
our in vitro study [12], in that the transulfuration pathway is
the primary pathway in the renal metabolism of homocys-
teine. The activity of the initial enzyme of transulfuration,
cystathionine-b-synthase was not affected by exposure of
rats to nitrous oxide. Recent studies of whole body homo-
cysteine clearance in folate- or cobalamin-deficient human
subjects do not support a major role for the re-methylation
pathway in the clearance of plasma homocysteine [37]. In
patients with chronic renal failure, whole body homocys-
teine clearance was 30% of control values, and was not
improved with high-dose folic acid supplementation [38].
Thus, in human studies, the kidneys have been suggested to
play an important role in clearing plasma homocysteine,
and that the re-methylation pathway does not appear to
contribute substantially to this clearance. However, direct
measures of renal homocysteine metabolism in human
subjects are required in order to quantitate the importance
of the human kidney for the metabolism of plasma homo-
cysteine.
In the present study, we have calculated the filtered load
of homocysteine, assuming ultrafilterability, as the product
of the glomerular filtration rate and the plasma-free homo-
cysteine concentration. The percentage of the total homo-
cysteine found in the free form in rat arterial plasma was 65
to 75%. Similar results have been reported previously for
rat plasma [39]. These results are in contrast to those
reported for human plasma, where the percentage of the
total homocysteine found in the free form is '30% [40].
Since only the free fraction of the total plasma homocys-
teine should be filtered, the close association we observed,
in rats, between the filtered load and the renal uptake of
homocysteine, at baseline concentrations, may indicate that
a lower fraction of total plasma homocysteine would be
available for filtration and subsequent metabolism in the
human kidney. Furthermore, homocysteine uptake from
the filtrate may partially explain the mode of action of
certain pharmacological agents that have been shown to
lower plasma total homocysteine concentrations in hu-
mans. The thiol agents pencillamine, mercaptoethanesulfo-
nic acid and n-acetylcysteine have been shown to reduce
total plasma homocysteine concentrations when adminis-
tered to humans [41–43]. These agents are thought to out
compete homocysteine for thiol binding sites on albumin,
thereby resulting in a greater fraction of the total plasma
homocysteine being present in the free form [43]. This
increase in the free fraction of homocysteine would pre-
sumably increase the filtered load and subsequent renal
metabolism of homocysteine, without significant increases
in the urinary excretion of homocysteine [43], thus leading
to lower plasma total homocysteine concentrations.
Concluding remarks
In the present study, we measured renal homocysteine
uptake during acute hyperhomocysteinemia, induced by
either a primed-continuous infusion of L-homocysteine or
the short-term exposure of rats to nitrous oxide. The results
obtained provide strong evidence that the kidney has a
substantial reserve capacity for metabolizing acute eleva-
tions in plasma homocysteine, as is evident from the data in
Figure 2. Furthermore, we provide in vivo evidence against
an essential role for the methionine synthase re-methyla-
tion pathway in the renal metabolism of plasma homocys-
teine during acute hyperhomocysteinemia. These data
serve to further characterize the role of the kidney in
homocysteine metabolism and position this organ as an
important site for the metabolic disposition of plasma
homocysteine.
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